Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Devlies W, Eckstein M, Cimadamore A, Devos G, Moris L, Van Den Broeck T, Montironi R, Joniau S, Claessens F, Gevaert T (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Cells MDPI

Book Volume: 9

Journal Issue: 11

DOI: 10.3390/cells9112494

Abstract

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

Authors with CRIS profile

Markus Eckstein Institute of Pathology

Involved external institutions

University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Università Politecnica delle Marche (UNIVPM) / Marche Polytechnic University IT Italy (IT) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven BE Belgium (BE)

How to cite

APA:

Devlies, W., Eckstein, M., Cimadamore, A., Devos, G., Moris, L., Van Den Broeck, T.,... Gevaert, T. (2020). Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. Cells, 9(11). https://doi.org/10.3390/cells9112494

MLA:

Devlies, Wout, et al. "Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer." Cells 9.11 (2020).

BibTeX: Download